ALUNBRIG® (brigatinib) Prescribing Information

ALUNBRIG® (brigatinib) Expert Opinion Video Series: Managing skin toxicities associated with ALUNBRIG

Dr Sharmistha Ghosh

Prescribing information is available at the top of the page.

Listen to Dr Sharmistha Ghosh discuss the management of skin toxicities which may occur in patients with ALK+ aNSCLC who take ALUNBRIG.

Dr Ghosh explains the recommended dose modifications for ALUNBRIG if patients experience skin toxicities as well as the guidance relating to photosensitivity and photodermatosis.

 

ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer.

To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.